Just because Wall Street likes a stock doesn't mean it's a great pick. However, it's not a bad idea to at least consider how ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Texas, on Wednesday published a 47-page report titled “The Case for Healthcare Freedom" as a roadmap to "Make American ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

A comprehensive new study supports evidence of the myriad health benefits of GLP-1 medications like Ozempic and Mounjaro — ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...